Navigation Links
InterMune Reports Third Quarter 2012 Financial Results And Business Highlights
Date:11/7/2012

luded and various authorizations are secured.
  • Spain – Considering a Royal Decree introduced in 2012 affecting health care expenditures and pharmaceuticals, and the continuing economic challenges of the country, forecasting of the timing of pricing and reimbursement decisions has become more challenging for all manufacturers.  As a result, InterMune currently believes that it is more likely that a decision regarding pricing and reimbursement of Esbriet in Spain will occur in the first half of 2013 than in the fourth quarter of this year.
  • The UK – InterMune today confirmed its previous guidance that the appraisal by the National Institute for Health and Clinical Excellence (NICE) is expected to be completed in March of 2013.  If NICE provides a positive appraisal for Esbriet, the company expects to launch Esbriet as soon as possible thereafter.
  • Mid-Sized Countries (MSC) – In addition to the seven MSC for which Esbriet pricing has been secured, the company expects to conclude pricing and reimbursement processes in the remaining three MSC of Netherlands, Finland and Ireland in the first half of 2013 and launch as soon as possible thereafter, assuming that acceptable pricing and reimbursement conditions are negotiated in these countries.
  • InterMune confirmed its earlier guidance that it expects to have launched Esbriet in all top 5 markets and 10 mid-sized markets in Europe, comprising 75 percent of the EU population and 80-85 percent of the European pharmaceutical market, in the second quarter of 2013, assuming acceptable pricing and reimbursement is secured. 
  • Enrollment of InterMune's Phase 3 pirfenidone study, ASCEND, in the United States and certain additional territories continues to proceed according to plans.  The company expects the study to be fully enrolled around the end of 2012, and that results from the study will be available in the first half of 2014.  AS
    '/>"/>

  • SOURCE InterMune, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10

    Related biology technology :

    1. InterMune To Release Third Quarter Financial Results On November 7
    2. InterMune To Present At JMP Securities Healthcare Conference
    3. InterMune to Release Fourth Quarter and Full Year Financial Results on February 9
    4. InterMune to Present at J. P. Morgan Healthcare Conference
    5. InterMune to Report Unaudited Fourth Quarter Esbriet® Revenue and Business Update on January 5
    6. PharmAthene Reports Third Quarter 2012 Financial Results
    7. VisionGate Reports Advances In Its Cell-CT(TM) Automated 3D Cell Analysis Platform At ASC 2012 Scientific Meeting
    8. Patient Safety Technologies Reports Third Quarter 2012 Results
    9. PDI Reports 2012 Third Quarter Financial Results
    10. Pharmacyclics Reports Fiscal 2013 First Quarter Financial Results and Multiple PCI-32765 Presentations at the 54th American Society of Hematology Annual Meeting
    11. Neurocrine Biosciences Reports Third Quarter 2012 Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/10/2014)... Deep Knowledge Ventures last week ... ‘Commercialising Longevity Research’ and welcomed a host of ... Bioscience Innovation Center for the event, organised by ... Ltd. The meeting highlighted the need for both ... age-related disease, as well as the crucial role ...
    (Date:7/10/2014)... (PRWEB) July 10, 2014 Unraveling life’s ... together. The Archer Family purchased a DNA ... DNA, but ended up with a lifetime of memories, ... within the family members’ DNA genuinely brought the family ... to search deeper into genetic history and prior to ...
    (Date:7/10/2014)... EvoDerma ’s NOOME Anti-Aging Motion has been upgraded for ... a second treatment cup to help prevent and smooth skin ... thinner on the edges for a softer contact with the ... surfaces on the face, neck and décolleté. Choose to use ... such as the cheeks and neck, or opt for the ...
    (Date:7/10/2014)... July 10, 2014 On July ... Medvedev , presented Russia,s first ... . The Company is developing a unique project called ... BIOCAD develops a number of innovative drugs based on ... The ceremony took place at the International Exhibition "Innoprom ...
    Breaking Biology Technology:DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 2DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 3DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 5DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 6Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 2Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 3Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 4Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 5Introducing a New Bonus Treatment Cup for EvoDerma’s NOOME Anti-Aging Motion 2Dmitry Medvedev Presented BIOCAD the First National "Industry" Award 2
    ... , , ... issue of the journal,Diabetic Hypoglycemia ( http://www.hypodiab.com ) reviews ... Professor Vincent Marks , a leading ... criminal behavior, discusses how,hypoglycemia-related neuroglycopenia can cause behavioral changes, which ...
    ... ... the company as a regulatory consultant after retiring from Eli Lilly & Co. ... science and human pharmaceutical products, including director of regulatory affairs and clinical research. ... US regulatory submissions. , ...
    ... ... ... 2010 -- Agriculture is a game-changer that addresses multiple global issues – hunger, poverty, ... CEO Ellen Kullman told attendees of the 40th World Economic Forum Annual ...
    Cached Biology Technology:Hypoglycemia - A Role in Criminal Behavior and a Consideration for Custodial Care 2Hypoglycemia - A Role in Criminal Behavior and a Consideration for Custodial Care 3Michael Langley, DVM, MBA, RAC Joins the Anson Group as a Regulatory Consultant 2DuPont Chair and CEO: Agriculture is Key to Global Economic Growth, Sustainability and Security 2
    (Date:7/11/2014)... 2014---A team of researchers from The Chinese University of ... gene of wild soybean linked to salt tolerance, with ... saline soil. This study published online in Nature ... genomic information for crop improvement. , Soybean is an ... human selection, cultivated soybeans have less genetic diversities than ...
    (Date:7/11/2014)... animals often develop relationships with other group members to ... wild chacma baboons the strategy for grooming activities shows ... just published in the scientific journal Biology Letters ... baboons is not practiced without ulterior motives. To be ... the individual, while grooming another individual can provide access ...
    (Date:7/11/2014)... two different ways that allow unprecedented experimental insights ... of oxygen molecules in photosynthesis. The two studies ... Nature Communications . , "The new knowledge will ... oxidation, which are key components for building artificial ... energy in fuels like hydrogen, ethanol or methanol," ...
    Breaking Biology News(10 mins):BGI reports a novel gene for salt tolerance found in wild soybean 2Baboons groom early in the day to get benefits later 2Molecular snapshots of oxygen formation in photosynthesis 2
    ... at the Stanford University School of Medicine have taken ... cells that could eventually be transplanted into living organisms. ... surgical resident Oscar Abilez, MD, and colleagues have successfully ... building blocks of blood vessels, after placing them in ...
    ... over a decade, the technique of distraction has been ... to reduce pain associated with certain medical procedures. The ... there is an important psychological element in the perception ... the harmful stimulus affecting the perception of the pain. ...
    ... of York have made a huge leap forward in the ... the Department of Biology has made a significant advance in ... biological warfare. , Bacteria like E. coli frequently try to ... called colicins, which are potent toxins. , The research ...
    Cached Biology News:Stanford doctors advance in bid to turn mice stem cells into blood vessels 2Stanford doctors advance in bid to turn mice stem cells into blood vessels 3Virtual realities against pain 2